Alto Neuroscience (NYSE:ANRO) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

Separately, Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Alto Neuroscience in a report on Thursday, May 15th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Alto Neuroscience Price Performance

Shares of ANRO opened at $3.40 on Monday. The company has a market cap of $92.18 million, a price-to-earnings ratio of -1.42 and a beta of 1.84. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $15.04. The company’s fifty day simple moving average is $2.71 and its 200 day simple moving average is $2.72. The company has a current ratio of 18.43, a quick ratio of 18.43 and a debt-to-equity ratio of 0.18.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). On average, research analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its position in shares of Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after acquiring an additional 3,139 shares during the period. Bank of Montreal Can bought a new stake in shares of Alto Neuroscience in the second quarter valued at about $25,000. Ground Swell Capital LLC bought a new stake in shares of Alto Neuroscience in the second quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Alto Neuroscience in the second quarter valued at about $33,000. Finally, Deutsche Bank AG boosted its position in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after acquiring an additional 3,629 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.